Back to search results
NCT05323253

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma

Active, Not Recruiting
NAAges 18+InterventionalTreatment
Alpha Tau Medical LTD.
~86 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:DaRT seeds

At a glance

Recruiting sites
0 of 28 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Objective Response Rate
Measured over From Day 14 until 52 weeks
+1 more outcome measured

Conditions

Recurrent Squamous Cell Carcinoma

Explore related trials

Skin Squamous Cell Carcinoma

NCT05323253

Where you'd take part

This study runs at 28 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Alliance Dermatology

    Phoenix, Arizonano site contact published

  • Banner Health MD Anderson Phoenix

    Gilbert, Arizonano site contact published

  • Baptist Health South Florida MCI

    Miami, Floridano site contact published

  • Bassett Healthcare Network

    Cooperstown, New Yorkno site contact published

  • Beer Dermatology

    West Palm Beach, Floridano site contact published

  • Belinson-Rabin Medical Center

    Petah Tikva, Israelno site contact published

  • Day Star Skin and Cancer Center

    DeLand, Floridano site contact published

  • Dermatology of Seattle and Bellevue

    Bellevue, Washingtonno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Liron Dimnik · STUDY_DIRECTOR · Alpha Tau Medical

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Leucocytes ≥3000mm3,
Absolute neutrophil count ≥1500mm3,
Platelets ≥100,000 mm3,
Total bilirubin ≤ 1.5xULN (upper limit of normal)
Aspartate Aminotransferase (AST) ≤2.5xULN,
Serum Glutamic-Oxaloacetic Transaminase (SGOT) ≤2.5xULN,
Serum Glutamic-Pyruvic Transaminase (SGPT) ≤2.5xULN,
Alkaline Phosphatase ≤2.5xULN.
Creatinine ≤ 2.0xULN or Creatinine Clearance ≥60 ml/min.
INR (International Normalized Ratio) or Prothrombin time ≤1.5xULN.

What this trial measures

  • Objective Response RateFrom Day 14 until 52 weeks

    Objective Response Rate (ORR) of DaRT as treatment for Recurrent SCC established by the confirmed Best Overall Response (BOR), with confirmation at least 4 weeks after initial assessment

  • Duration of Response6 months from from first demonstration of CR or PR after Alpha DaRT seeds insertion.

    Assess the Duration of Response (DOR) of DaRT as treatment for Recurrent SCC